Major Stock Movers on Wednesday: LAC, NKE, and Others
U.S. Government Shutdown Impact: Stock futures declined as the U.S. government shutdown began after the Senate rejected a short-term funding bill, leading to the suspension of non-essential federal operations.
Stock Movers: Lithium Americas shares surged by 35% following a government stake acquisition announcement, while Nike's shares rose 5% after a better-than-expected Q1 report despite future revenue concerns. Conversely, Enanta Pharmaceuticals' shares dropped 8% due to a public offering announcement.
Trade with 70% Backtested Accuracy
Analyst Views on ENTA
About ENTA
About the author
Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme
- FDA Approval: Agios Pharmaceuticals announced that its drug Aqvesme received FDA approval, becoming the only treatment for non-transfusion-dependent and transfusion-dependent alpha or beta-thalassemia, which is expected to significantly enhance its market competitiveness.
- Stock Price Rebound: Following the FDA approval announcement, AGIO's stock surged 18.6% to $29.17, with trading volume exceeding average levels, indicating strong investor confidence in the company's prospects.
- Earnings Outlook: Although the upcoming quarterly report is expected to show a loss of $1.96 per share, a 12.6% year-over-year decline, revenues are projected at $11.14 million, reflecting a 3.8% increase from the previous year, demonstrating resilience amid challenges.
- Market Attention: AGIO's consensus EPS estimate has remained unchanged over the past 30 days, and despite the stock's rise, investors should monitor future earnings estimate revisions to assess whether the stock can maintain its upward momentum.
JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook
JP Morgan Coverage Initiation: On November 14, 2025, JP Morgan began coverage of Enanta Pharmaceuticals (NasdaqGS:ENTA) with an "Overweight" recommendation, projecting a 62.04% upside based on an average one-year price target of $19.53/share.
Projected Revenue and EPS: Enanta Pharmaceuticals is expected to see a significant increase in annual revenue, projected at $834 million, which represents a 1,186.29% growth, alongside a projected non-GAAP EPS of 10.27.
Institutional Ownership Trends: There are currently 275 funds reporting positions in Enanta Pharmaceuticals, with a slight increase in ownership and a total of 20,591K shares held by institutions, reflecting a 1.16% rise over the last three months.
Shareholder Activity: Notable changes in shareholder positions include Janus Henderson Group increasing its stake by 111.20%, while Millennium Management reduced its holdings by 53.85%, indicating varied strategies among institutional investors.
